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Natural killer (NK) cells provide an initial host immune response to infection by many viral pathogens. Consequently, the viruses
have evolved mechanisms to attenuate the host response, leading to improved viral ﬁtness. One mechanism employed by members
of the β-herpesvirus family, which includes the cytomegaloviruses, is to modulate the expression of cell surface ligands recognized
by NK cell activation molecules. A novel set of cytomegalovirus (CMV) genes, exempliﬁed by the mouse m145 family, encode
molecules that have structural and functional features similar to those of host major histocompatibility-encoded (MHC) class I
molecules, some of which are known to contribute to immune evasion. In this review, we explore the function, structure, and
evolution of MHC-I-like molecules of the CMVs and speculate on the dynamic development of novel immunoevasive functions
based on the MHC-I protein fold.
1.Introduction
Mammalsaresusceptibletoawiderangeofinfectiousagents,
including, but not limited to, viruses, bacteria, and proto-
zoan parasites. While many microbes cause debilitating ill-
nesses, are responsible for much morbidity and mortality
worldwide, and garner much of the public’s attention, other
organisms stealthily invade their hosts, establish lifelong
infection, and remarkably, cause little or no symptoms in
healthy individuals. CMVs are examples of microbes that
establish asymptomatic, latent, and lifelong infections, re-
vealing themselves only when the host’s immune system is
compromised. Virus survival in the face of an intact immune
system is accomplished through subversion of antiviral
immunity by an arsenal of virally encoded proteins, termed
immunoevasins, that speciﬁcally target key molecular recog-
nitionstepsnecessaryforanimmuneresponse.Theinterplay
of evolutionary diversiﬁcation of immunoevasins with the
defense mechanisms of the host results in a dynamic balance
permitting the survival of both the host and the infectious
organism. Among the many viral infections of fundamental
interest that have been well studied are the species-speciﬁc
large DNA viruses of the β-herpesvirus family, of which the
CMVs are representative members [1, 2]. The human CMV
(HCMV) as well as its murine relative (MCMV) [3]a n d
other species such as the guinea pig (GPCMV) [4], rhesus
(RhCMV) [5–9], and chimpanzee (CCMV) [10, 11]h a v e
been the subject of recent studies designed to understand
not only the basic genetics, biochemistry, and biology of
these complex organisms but also to discern the immune
responses of their hosts, with an ultimate goal of developing
eﬀectivevaccinestoalleviatepathogeniceﬀectsoftheviruses.
MCMVinfectionisamodelforHCMVinfectioninhumans,
because of similarities in viral life cycle, genome structure,
and host immune response [12–15]. These viruses exhibit
similarities in the life cycle of acute infection, persistence and2 Journal of Biomedicine and Biotechnology
latent infection or superinfection, and reactivation under
conditions of immune suppression [8, 16]. The subject of
this review is a structural, genetic, and functional analysis of
a set of genes and their encoded glycoproteins that have been
adapted by MCMV to assure the continued survival of the
virus. Because of the structural similarities of these encoded
proteins to MHC-I and other MHC-I-like molecules of the
host, we argue that these molecules were derived from lateral
(horizontal) genetic transmission from host to virus.
HCMV is a serious and opportunistic pathogen that
aﬀects 45–100% of the adult population. Seroprevalence is
inﬂuencedbyage,raceandethnicity,sex,andsocioeconomic
status where frequency of infection is highest in urban areas
[17]. Primary infections are usually asymptomatic in healthy
individuals but can cause signiﬁcant morbidity in immuno-
compromised patients such as those with AIDS or cancer,
and in individuals undergoing therapeutic immunosuppres-
sion in the course of solid organ transplantation. Congenital
infection resulting from primary maternal infection that has
a rate of 1–4% is also a major concern, leading to long-term
sequelae such as neurodevelopmental disabilities, including
mental retardation and sensorineural hearing loss [18].
2.Background
2.1. The Immune Response to CMV Infection. Mammalian
cells possess sophisticated mechanisms that telegraph their
health status to the cell surface for recognition by inﬂam-
matory and immune cells. The vertebrate host responds to
CMV infection using the full battery of specialized cells of
the immune system: NK-cells, B cells, and T cells of both
cytolytic (CD8+) and helper (CD4+) lineages. Aspects of
both acute and chronic CMV disease may be controlled by
antibodies, NK,andothercellsoftheinnateimmunesystem,
as well as by CD8+ and CD4+ T cells. Such cells of the
immunesystemcaneitherdirectlykillthevirus-infectedcells
or produce bioactive molecules that exert direct and indirect
eﬀects on the innate and adaptive arms of the immune
response. Two main cellular mechanisms alert the immune
system to an infected or stressed state: NK-cell and T-cell
recognition and activation.
During viral infection, NK-cells oﬀer an important ﬁrst
line of defense that limits viral expansion at a time when
speciﬁc immunity has not yet fully developed. But the virus
has evolved countermeasures to balance this formidable NK
surveillance [19] (see Figure 1). Following the initial NK
response, the host develops adaptive CD8+ and CD4+ Tc e l l
responses [20–22].
2.2. Viral Evasins. V i r u s e sh a v et w om a j o rl i f ec y c l ea d v a n -
tagesthatallowthemtocounterthehost’simmuneresponse:
their rapid generation time permits them to accumulate
genetic variants that allow them to subvert the immune
response, and viruses with large genomes have the capacity
to devote extensive amounts of genetic material to functions
that may provide even slight evolutionary advantage. As
a group, the CMV have genomes that are colinear as in
the case of MCMV and HCMV, that may be as large as
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Figure 1: MCMV-encoded proteins disrupt NK-cell recognition of
infected cells. During MCMV infection, the surface expression of
thestress-inducedmolecules,ligandsforNKG2D,isdownregulated:
m152 downregulates all isoforms of RAE-1, m145 and m155 inter-
fere with H60 and MULT-1, respectively, and m138 downregulates
H60, MULT-1, and RAE-1ε (a). m157 binds both inhibitory NK
receptor, Ly49I, and activating NK receptor, Ly49H (b).
230kb, and that encode as many as 170 open reading frames
(ORFs), of which about one-third is required for essential
viral functions. About half of the identiﬁed genes in MCMV
have HCMV homologues [23, 24]. Although the genetic and
functional analysis of all of these genes has not yet been per-
formed, studies of many of them indicate a role in curtailing
NK-cellrecognitionofthevirus-infectedcellorininterfering
with antigen processing and presentation to CD8+ T cells. Of
particular interest to our studies of MHC-I-like molecules
of the virus is the m145family of genes (m17, m145 to
m158), several of which have been shown to contribute to
viral ﬁtness. (Originally denoted the m145 family, current
BLAST [25] searches of the protein database identify theirJournal of Biomedicine and Biotechnology 3
encoded proteins as members of the “m157 superfamily.”)
Remarkably, most of these genes map to the extreme right
end of the MCMV genome while the more highly conserved
essential functions of the virus map to the center. Also,
anothersetofgenes,someofwhichplayasimilarroleimmu-
noevasion, map to the extreme left of the MCMV genome.
These are known as the m02 family (genes m02 to m16) and
some evidence suggests that they can impair T-cell receptor-
mediated recognition of MHC-I/peptide complexes that lead
to CD8+ T-cell activation [26, 27].
2.3. NK Receptors in Viral Infection. During the early stages
ofMCMVinfection,thehostimmuneresponseisdominated
by NK-cell activation and the resulting cytolysis of virus-
infected cells. The activation of NK-cells is regulated by a
balance of signals delivered through activating or inhibitory
receptors. These surface molecules either bind classical
M H C - Im o l e c u l e so rM H C - Ih o m o l o g u e sa n da r ec l a s s i ﬁ e d
into two families: C-type lectin-like (Ly49, NKG2D and
CD94/NKG2) and immunoglobulin-like (KIRs and LIRs) as
reviewed elsewhere [28–30].
2.4. NKG2D. The infected cell initiates a complex stress
response, leading to increased cell surface production of
a spectrum of molecules including MICA or MICB, and
members of the ULBP family in the human [31–34], or
RAE-1 (α,β,γ,δ,ε), MULT-1, and H60 in the mouse [35–
39]. These MHC-I-like stress-induced cell surface molecules
are ligands for the NK-cell activation receptor, NKG2D, the
best characterized NK activating receptor. NKG2D lacks a
signaling motif of its own, and thus requires association
with either the DAP10 or DAP12 adapter molecules [40].
In the mouse, NKG2D Short pairs with either DAP10 or
DAP12 [41, 42], while NKG2D Long interacts exclusively
with DAP10. Human NKG2D, by contrast, only has the L
isoform and thus interacts exclusively with DAP10 [43]. The
direct interaction of NKG2D with any of the NKG2D ligands
activates the NK-cell and initiates its cytokine and cytolytic
program, resulting in the killing of the virus-infected cell.
To counter host NK surveillance, the virus has evolved
strategies to attenuate the host cell expression of the NKG2D
ligands, which it accomplishes through the expression of
some m145 family members early in infection. In particular,
the m152, m145, and m155glycoproteins, as well as the
unrelated m138, each downregulates one or more NKG2D
ligands. m152, encoding the gp40 glycoprotein, not only
controls the surface expression of classical MHC-I, but
also downregulates surface expression of RAE-1 molecules.
Although this regulatory function of m152 has been recog-
nized for several years [44, 45], evidence for direct inter-
action of m152 with RAE-1 has only been demonstrated
recently. Studies show binding of m152 with RAE-1
isoforms β,γ,a n dδ and establish a relationship between the
effectiveness of RAE-1 attenuation with the intrinsic aﬃnity
of the m152/RAE-1 interaction [46]. In a manner similar
to that of the m152/RAE-1 interaction, the m145-encoded
glycoprotein downmodulates the expression of MULT-1
[47], and m155 blocks H60 surface expression [48]. m138,
originally considered a viral Fc receptor, also regulates both
MULT-1 and H60 as well as RAE-1ε. In addition, it also
aﬀects B7-1 (CD80) expression on dendritic cells (DCs)
which impairs DC stimulation of CTLs [49]. The functions
of these MCMV genes have been established in part by the
judicious exploitation of deletion viruses such as the Δm152
mutant, that clearly fails to downregulate both MHC-I
and RAE-1 [45, 50], the Δm138 mutant that is deﬁcient
in H60 and MULT-1 regulation, and the Δm155 virus that
attenuates the NK response in vivo and partially restores H60
expression on virus-infected cells [48].
The intriguing structural question raised by the paired
interactions of members of the m145 family with NKG2D
ligands is how precisely do these viral MHC-I-like molecules
function. The high-resolution X-ray crystallographic struc-
tures of several of these viral MHC-I-like molecules are now
known. In addition, the structures of some of the NKG2D
ligands have been determined. These structures oﬀer further
insight not only into the function of the viral MHC-I-like
molecules, but also into their evolution.
2.5. Ly49 Receptors. Major advances in our understanding
of the role of NK receptors in the immune response to
viral infection derived from studies of the Ly49 family in
the mouse and of the KIR family in the human. These are
cell surface receptors, expressed primarily on NK-cells, that
interact either with host classical MHC-I molecules, or, in
several notable examples, with virus-encoded ligands. The
Ly49 family members are either inhibitory (such as Ly49A,
Ly49C, or Ly49I), or activating (such as Ly49H or Ly49P).
Similar functions are contributed by the KIRDL inhibitory
receptors and the KIRDS activating receptors in the human,
but our discussion will be conﬁned to the mouse molecules.
The inhibitory receptors, with Ly49A serving as the
prototype, recognize classical MHC-I on host cells, and thus
deliver a tonic inhibitory signal to the NK-cell, through
theircytoplasmicimmunoreceptortyrosine-basedinhibition
motifs (ITIMs). With decreased MHC-I expression on the
virus-infected cell, the strength of the inhibitory signal
decreases, and concurrent activating signals dominate, lead-
ing to lysis of the virus-infected cell. Such a mechanism,
the basis of the missing self-hypothesis [51]h a sb e e nw e l l -
characterized for the interaction of Ly49A with its MHC-
I ligand H-2Dd [52, 53]. The importance of interactions
of Ly49A and other inhibitory receptors with their MHC-I
ligands in NK-cell education or licensing has also recently
been explored [54, 55].
S o m ea c t i v a t i n gr e c e p t o r ss u c ha sL y 4 9 H ,i nc o n t r a s tt o
NKG2D, which exploits stress-induced ligands, do not have
known self-MHC-I ligands, but instead interact strongly
with some CMV-encoded molecules. Ly49H is expressed in
MCMV-resistant mouse strains and binds a viral member of
the m145 family, m157, which is expressed at the cell surface
as a glycophosphatidylinositol (GPI)-linked glycoprotein
earlyin infection. Ly49H deﬁcientmiceareMCMVsensitive,
and transgenic expression of Ly49H conﬁrms that this
activating receptor alone can account for viral resistance.
In mouse strains susceptible to MCMV infection such as4 Journal of Biomedicine and Biotechnology
129/J, there is no Ly49H gene, but rather one encoding
an inhibitory receptor Ly49I129, that interacts strongly with
m157 [56, 57]. Thus, it would appear that m157 evolved
initially in the setting of hosts that expressed Ly49I-like
activities, resulting in improved viral survival. As the virus
became more virulent, mouse evolution settled on the
solution of shuﬄing the Ly49I-binding activity (residing
in its extracellular domain) onto the signaling module of
an activating receptor and thus became Ly49H, conferring
resistance to viruses that express m157 [58]. In experiments
designed to examine the evolution of virus resistance to host
NK activity, it was shown that when MCMV is passaged
repeatedly through resistant Ly49H+ mice, m157 mutations
accumulate rapidly, permitting the virus to escape the NK
immunosurveillance due to Ly49H [59]. Recent studies of
a variety of naturally occurring m157 variants indicate that
many are incapable of binding Ly49H (from C57BL/6), but
can interact with Ly49C inhibitory receptors from several
diﬀerent strains [60]. Thus, the eﬀects of the diﬀerential
interactions of Ly49 activating and inhibitory NK receptors
on the evolution of viral MHC-like ligands, such as m157,
mayprovetobeevenmorecomplexthanpreviouslythought.
There are some mouse strains that lack Ly49H but
are resistant to MCMV infection through other NK-cell-
mediated mechanisms. An example is the Ma/My mouse
whose resistance is genetically dependent on the presence
of genes encoding an activation receptor Ly49P, and H-2Dk
[61]. Epistatic interactions of these genes (or their gene
products) confer resistance to MCMV. The Ly49P dependent
activation of NK-cells is blocked by an antibody to H-
2Dk [61, 62]. In addition to H-2Dk and Ly49P, the viral
resistance of Ma/My also requires m04, a gene encoding
gp34, a glycoprotein that escorts MHC-I to the surface and
that inhibits recognition by CD8+ CTL. A Δm04 mutant of
MCMV abrogates the resistance of Ma/My mice [30, 62, 63].
The mechanism by which these three gene products, Ly49P
and H-2Dk of the host, and m04 of MCMV, cooperatively
generate viral resistance remains unclear.
3. Biochemistry, Structure,and Evolutionof
ViralMHC-I-LikeMolecules
3.1. Interaction of MHC-I-Like MCMV Molecules and NK
Receptors. Studies of the function of the MHC-I-like genes
of the CMVs have largely relied on experiments with mutant
viruses with engineered deletions of the relevant genes, on
detection of cell surface expression of host proteins following
infection or transfection, or on immunoprecipitation (pull-
down) experiments using speciﬁc antibodies. Although such
experiments support the conclusions that some of these viral
MHC-I-like molecules either downregulate or impair the
recognition of particular ligands, they fail to explain the
precise molecular mechanism(s) involved in such regulatory
eﬀects [39, 44, 50]. To this end, several laboratories have
directed eﬀorts to engineer recombinant forms of the viral
MHC-I-like proteins and their ligands and to measure these
interactions in well-deﬁned in vitro systems. Speciﬁcally, the
interactions of MCMV m152 [46]and m157 [64, 65]and of
HCMV UL18 [65] have been examined in this way.
The engineering, expression, and puriﬁcation of soluble
forms of the extracellular domains of m152 and RAE-1β,- 1 γ
(expressedinBALB/c),andRAE-1δ (C57BL/6)generatedthe
reagents for size exclusion binding assays, analytical ultra-
centrifugation (AUC), and isothermal titration calorime-
try (ITC), based on the hypothesis that the ectodomains
m152 and RAE-1 isoforms interact directly. Recombinant
m152, prepared in insect cells, interacted well with RAE-1
molecules refolded from E. coli inclusion bodies. Aﬃnities
for the interactions were measured by AUC with Kdso f
RAE-1γ (1μM) > RAE-β(3μM) > RAE-1δ (30μM) [46],
which may be compared with the Kd of the interaction of
murine NKG2D with several RAE-1 isoforms (340–730nM)
[66]. The hierarchy of aﬃnities of the diﬀerent isoforms
paralleled the eﬀectiveness in the downregulation of RAE-1
by m152. In addition, these studies conﬁrmed the predicted
1:1 stoichiometry of the m152:RAE-1 interaction.
T h ei n t e r a c t i o nb e t w e e nm 1 5 7a n dL y 4 9N Kr e c e p t o r s
was ﬁrst detected using m157-fusion proteins [56], or using
an Ly49H-reporter cell and an m157 transfectant [67].
In experiments employing recombinant m157, Ly49H, and
Ly49I and surface plasmon resonance (SPR) as well as ITC,
the aﬃnity of Ly49I for m157 was determined to have a Kd
of 0.2μM with a 1:1 stoichiometry, a stronger aﬃnity than
Ly49’s interaction with standard MHC-I ligands (1–80μM)
[64, 68, 69].
UL18, an HCMV molecule that interacts with LIR1 (also
known as ILT2 or CD85j), an inhibitory receptor expressed
widelyonmonocytes,DCs,Bcells,andsomeTcellsandNK-
cells, has also been studied quantitatively by SPR methods.
The interaction of LIR1 with UL18 (Kd ∼ 10
−2μM) is
>1000-fold stronger than that of LIR1 with classical MHC-
I[ 65]. It is interesting to note that the physical interaction
between UL18 and the human NK-cell activating receptor,
NKG2C/CD94, has been estimated to have a Kd of about 10
to 100μM[ 70].
The quantitative measure of direct binding interactions
between viral MHC-I like proteins and their ligands reﬂects
the strength with which these evasins can compete with
host protective or inhibitory mechanisms. Knowledge of the
structural details of these interactions contributes to our
understanding of the evolution and molecular mechanism of
such viral MHC-I mimics.
3.2. Structural Characteristics of CMV MHC-I-Like Molecules
3.2.1. Amino Acid Sequence Similarities. The ﬁrst CMV gene
identiﬁed as an MHC-I homolog was H301 (now known
as UL18) of HCMV, which was shown to encode a protein
with 20% similarity to classical MHC-I proteins [71]. Subse-
quently, with the complete DNA sequence determination of
the MCMV genome and bioinformatic analysis of its ORFs
[23], m144 was shown to have amino acid sequence similar-
ity to classical MHC-I proteins. Reexamination of ORFs of
MCMV using more recently developed computational tools
suggested the existence of other genes that encode MHC-
I-like molecules [72]. Simple alignment of classical MHC-I
molecules from human and mouse reveals obvious sequenceJournal of Biomedicine and Biotechnology 5
similarity over 267amino acid residues of the extracellular
domain with scores of 81% similarity and 71% identity
(see Figure 2(a)). When UL18 and m144 are included in
the sequence alignment, similarities, particularly in the
conservation of cysteine residues, are still evident, although
UL18 is only 24% identical with HLA-A2, and m144 is about
19% identical to H-2Dd (Figure 2(b)). However, eﬀorts to
alignallthemembersofthem145familyfromMCMVreveal
profound diﬀerences in sequence and considerable problems
in selecting appropriate computational parameters for the
bestalignment(Figure 2(c)).Sequenceidentityscoresforthe
m145 family as compared with the classical MHC-I molecule
H-2Dd range from 6.2 (for m151) to 24.4% (for m144).
These rather marginal sequence similarities and the
inherent ambiguities in evaluating the alignments of cysteine
residues demand a more objective three-dimensional struc-
tural comparison.
3.2.2. Three-Dimensional Structures of Viral Evasins. The
structures of three members of the m145 family (m144 [73],
m153 [74], and m157 [64]) have been solved, as well as those
of the HCMV UL18 [75, 76]. In addition, a putative evasin
of the tanapox virus 2L, which, remarkably, is also an MHC-
I-like molecule [77] ,h a sb e e ne x a m i n e di ns t r u c t u r a ld e t a i l .
Furthermore, structures of several other HCMV molecules,
US2 and UL16, that function as immunoevasins, but are
structurally related to the immunoglobulin superfamily and
not related to the MHC-I family, have also been determined
[78, 79].
Early studies of m144 suggested that it inhibited the
recognition of virus-infected cells by NK-cells in vivo [80],
and that m144 expression in tumor cells conferred resistance
to NK-cell killing [81]. However, these results are controver-
sial and there remains no consensus as to the function of the
m144 glycoprotein.
Our lab has examined the expression and structure of
m144 [73](PDB [82] code 1U58) (see Figure 3, Table 1).
Biochemical analysis [83] of m144 revealed the lack of co-
purifying bound peptides, a result conﬁrmed by transfection
studies[73]thatrevealedthelackofarequirementforbound
peptide for cell surface expression. The X-ray structure [73]
shows a typical MHC-I fold consisting of α1a n dα2h e l i c e s
supported by a ﬂoor of antiparallel β strands and connected
via a loop to an immunoglobulin-like α3 domain. Although
m144 cocrystalized with β2-microglobulin (β2m), located in
a canonical position beneath the β strand ﬂoor, expression
studies [42, 84] showed that there is no absolute β2m
requirement for folding and cell surface display. The α1α2
domain unit is stabilized by two disulﬁde bonds: one that
is similar in orientation to that found in classical MHC-I
molecules (joining the β5 strand to the α2 helix) and another
unique one that links the α1h e l i xt oβ4. The disulﬁde in the
immunoglobulin-like α3 domain is conserved. The structure
revealstruncatedα1andα2helices,anarrowedgroove,anda
modiﬁedβ2minterface.Anunstructuredstretchof13amino
acids not seen in the electron density map may be indicative
of a ﬂexible part of the molecule stabilized by a molecular
partner [73].
The structure of m153 another member of the m145
family, with unknown function, has also been determined
[74] (see Figure 3, Table 1). It was expressed and crystallized
in the absence of β2m, which is not required for its
cell surface expression. m153 is a noncovalently associated
homodimer, not only in its crystal form but also as a puriﬁed
protein and as expressed at the cell surface. m153 dimerizes
in a head-to-tail fashion. Its aminoterminus is somewhat
longerthanthatofclassicalMHC-Imoleculesandistethered
to its extended H2b helix via a disulﬁde bond. Another novel
disulﬁde bond closes the loop connecting two β strands,
and a third disulﬁde, similarly positioned to that of classical
MHC-I, is in the α3 domain. Like m144, it has a narrow
potential binding groove, not apparently large enough to
engage a peptide ligand. The tight juxtaposition of the α1
and α2 helices exposes a signiﬁcant portion of the β sheet
ﬂoor. A coiled region separates the amino from the carboxyl-
terminalpartsoftheα2helix.Althoughthefunctionofm153
remains as a conundrum, reporter cells constructed with the
m153 extracellular domains indicate that some subsets of
murine lymphoid cells ligate m153 and activate the reporter
through this interaction [84]. Sequence alignment of m153
protein from diﬀerent MCMV isolates identiﬁes a conserved
motif suggestive of an unchanging speciﬁc function [74,
87]. Although a deﬁnitive function for m153 has yet to be
identiﬁed, m153 may play an important role in the viral life
cycle as it is expressed early in infection and accumulates at
the cell surface [84].
m157, a 37kD surface GPI-linked glycoprotein that is
not required for viral replication in vitro, is the only known
CMV-encoded cell surface molecule that can engage both
NK activating (Ly49H) and inhibitory receptors (Ly49I)
[56, 72]. The structure of m157 [64] showcases a recog-
nizable MHC-I fold with neither peptide binding groove
nor β2m association and a compactness enhanced by
extensive intramolecular interactions. m157, like m153, has
an extended aminoterminus, but for m157 this is a unique
helical region, designated α0 (see Figure 3, Table 1). As
with m144 and m153, the α1 juxtaposition to α2p r e c l u d e s
binding to a peptide antigen. Two intrachain disulﬁde bonds
stabilize the α1α2 domain, and the α3 domain has a disulﬁde
as well. α2 is joined to α3 by an extended H2b helix,
similar in conformation to that of m153. Mutagenesis and
binding analysis suggest that m157 engages its Ly49H or
Ly49I ligands through a surface distinct from that by which
the homologous Ly49A binds to its H-2Dd ligand.
TheHCMVUL18iscloserinstructuretoclassicalMHC-
I molecules and to m144 than it is to m153 or m157 despite
the fact that it is only about 25% identical in sequence to
MHC-I. UL18 requires peptide and β2m for proper folding
[88], and binds the host inhibitory receptor LIR-1 with
high aﬃnity [75]. The α1α2 domain preserves the highly
conserved disulﬁde of MHC-I molecules, and also has a
canonical disulﬁde bridge in the α3 domain. In addition, it
links two adjacent β strands of α3 with another disulﬁde (see
Figure 3, Table 1). Both α3 domain disulﬁdes are necessary
for proper association with the LIR-1 ligand [89, 90].
The three-dimensional structure of the 2L protein,
another MHC-I homologue [85] of the human tanapox6 Journal of Biomedicine and Biotechnology
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Figure 2: Amino acid sequence alignments of the extracellular domains of classical MHC-I molecules from mouse (H-2Dd) and human
(HLA-A2) with MHC-I-like viral immunoevasins were generated using ClustalW module of MacVector 10.6.6. H-2Dd and HLA-A2 share
signiﬁcant similarity at 81.7% (a). UL18 and m144 show detectable sequence similarity (21–40%) with HLA-A2 and H-2Dd.C o n s e r v e d
cysteine residues are in yellow (b). The alignment of m145 family members and other MHC-I-like immunoevasins shows 6–40% sequence
similarity to the canonical MHC-I molecules (c).Journal of Biomedicine and Biotechnology 7
Table 1: (a) Subunit composition of MHC-I and MHC-I-like viral molecules. (b) Structural diﬀerences among MHC-I and MHC-I-like
viral molecules.
(a)
Molecule β2m Bound peptide ligand
Classical MHC-I (e.g., HLA-A2, H-2Dd)y e s y e s
Viral MHC-I-like molecule
UL18 yes yes
m144 yes no
m153 no no
m157 no no
2L no no
(b)
Molecule
Peptide
binding
groove
N-terminal
extension H2b helix
Canonical -S-S- Non-canonical -S-S-
α1α2d o m a i n
β5→ α2
α3d o m a i n
β2→ β6 α1α2d o m a i n α3d o m a i n
Classical MHC-I
(e.g., HLA-A2, H-2Dd) yes no short yes yes no no
Viral MHC-I-like
UL18 yes no short yes yes no β4→ β5
m144 no no short yes yes β2→ α1n o
m153 no Strand, coil long no yes β4→loop 5 N-term→H2b
m157 no α0 helix long no yes Loop 4 β5→ β6
2L no no no no yes no C-term loop
virus, has also been determined [77]. Tanapox is a Yat-
apoxvirus,onlydistantlyrelatedtotheHerpesviridae towhich
the CMVs belong. The 2L molecule binds TNF-α, in a high-
aﬃnity interaction that accounts for inhibition of immune
function such as TNF-mediated cellular cytotoxicity. The
X-ray structure of the complex of 2L with TNF-α reveals
a molecule that lacks the typical MHC-I peptide binding
groove. The amino-terminal parts of the α1a n dα2h e l i c e s
are displaced toward the opposite helix, closing the groove.
One disulﬁde bond links the β strand ﬂoor to the α2h e l i x
like classical MHC-I molecules, while two others stabilize
the α3 domain (see Figure 3, Table 1). The site of interaction
between 2L and TNF-α is a large and complementary
interfacethatincludesresidueofboththeα2andα3domains
of 2L. Thus, 2L preserves the basic MHC-I fold, lacks peptide
orβ2m,andinteractswiththetrimericTNF-αinanovelway.
4. ViralMHC-I-LikeGeneEvolution
CMVs and their respective hosts have coevolved, and the
origin of the most recent common root for the three families
of the Herpesviridae (i.e., the α,β,a n dγ-Herpesvirinae)h a s
been estimated to have occurred about 400 millionyears
ago (Ma) [91]. Under the selection of the host immune
response, the virus has developed biological solutions for
its continued survival. Although a conserved core of genes
is observed for the herpesvirus genomes [92], there exist
a number of genes, homologous to those of the host [93]
which appear to have originated in the host and to have
been acquired by lateral (horizontal) transmission. There are
many viral genes that on initial evaluation exhibit a very low
level of nucleic acid sequence similarity to host genes, but
whose ORFs likely encode proteins similar to those of the
host. Even more distantly related viral genes are observed,
some of which encode proteins that have little or no amino
acid sequence similarity to proteins from their hosts, but
whose relationship to host proteins may be deduced through
various secondary structure threading programs such as 3D-
PSSM [94, 95]o rp h y r e[ 96, 97]. The viral MHC-I-like
proteins fall into this latter category, revealing amino acid
sequence identity as low as 6%. The evolutionary origin of
many of these proteins and their encoding genes, although
they seem to have been derived from the host, remains
unclear, and eﬀorts to understand their origin rely not
only on nucleic acid and protein sequence comparison,
but also on a knowledge of the function and structure of
the expressed proteins. With the goal of understanding the
function and evolution of these genes, several laboratories
have determined the three-dimensional structure of repre-
sentative viral MHC-I-like molecules, and the comparisons
that we have summarized above conﬁrm that m144, UL18,
m153, m157 of the CMV family, and 2L of the more distantly
related tanapox virus all clearly have structural features in
common (see Table 1). The structural similarity of each of
these proteins to other MHC-I, for example, H-2Dd [86]
and MHC-I-like molecules is established not only by an
intuitive sense based on the similarity of the location and
orientation of secondary structural elements, it is strongly8 Journal of Biomedicine and Biotechnology
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Figure 3: X-ray structures of m157 (2NYK) [64], m153 (205N) [74, 84], m144 (IU58), HCMV UL18 (3D2U) [75], Tanapox 2L protein
(3IT8) [85], and H-2Dd (3ECB) [86] reveal both shared and unique features. The disulﬁde bonds are in yellow. The α1, α2 and H2b helices
and α3 domain are labeled. Ribbon diagrams of the structures in (a), rotated 90◦ to the right in (b), reveal diﬀerences in β2m and peptide
binding (a, b). The view from the top shows diﬀerences in the peptide binding pocket (c). Illustrations were prepared from the superposed
structures of the molecules using PyMOL http://www.pymol.org/.
conﬁrmed by quantitative computational superpositions of
the crystallographic structures calculated with programs
such as Dali [98], Pymol [99], and lsqkab [100].
Thus, arguments for the relationship of these representa-
tiveproteinsandtheirencodinggenescanbemadeforcefully.
In addition, particularly among the rodent members of the
145 family, the amino acid sequence similarities support the
notion of a common ancestor. The most diﬃcult problem is
whether or not a single evolutionary event, in which a gene
encoding a vertebrate MHC-I-like molecule was captured by
as i n g l el a r g eD N Av i r u sa sm u c ha s4 0 0M a ,h a sg i v e nr i s e
to the genes that encode MHC-I-like molecules identiﬁable
in a number of viral species, or whether several independent
capture events have occurred for diﬀerent viruses. The
observation that the HCMV protein UL18 and the MCMV
protein m144 appear to be closer in structure to classical
MHC-I molecules and that the other MCMV proteins,
m153 and m157, are more distantly related, favors a single
ancient origin. Whether such a hypothesis can withstand the
identiﬁcation, amino acid sequence, and structural analysis
of previously unidentiﬁed CMV and other viral immuno-
evasins related to classical MHC-I molecules remains to be
determined.
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